Literature DB >> 28266877

Glucuronidation: driving factors and their impact on glucuronide disposition.

Guangyi Yang1,2, Shufan Ge3, Rashim Singh3, Sumit Basu3, Katherine Shatzer3, Ming Zen4, Jiong Liu5, Yifan Tu3, Chenning Zhang1, Jinbao Wei1, Jian Shi6, Lijun Zhu6, Zhongqiu Liu6, Yuan Wang7, Song Gao3,7, Ming Hu3,7.   

Abstract

Glucuronidation is a well-recognized phase II metabolic pathway for a variety of chemicals including drugs and endogenous substances. Although it is usually the secondary metabolic pathway for a compound preceded by phase I hydroxylation, glucuronidation alone could serve as the dominant metabolic pathway for many compounds, including some with high aqueous solubility. Glucuronidation involves the metabolism of parent compound by UDP-glucuronosyltransferases (UGTs) into hydrophilic and negatively charged glucuronides that cannot exit the cell without the aid of efflux transporters. Therefore, elimination of parent compound via glucuronidation in a metabolic active cell is controlled by two driving forces: the formation of glucuronides by UGT enzymes and the (polarized) excretion of these glucuronides by efflux transporters located on the cell surfaces in various drug disposition organs. Contrary to the common assumption that the glucuronides reaching the systemic circulation were destined for urinary excretion, recent evidences suggest that hepatocytes are capable of highly efficient biliary clearance of the gut-generated glucuronides. Furthermore, the biliary- and enteric-eliminated glucuronides participate into recycling schemes involving intestinal microbes, which often prolong their local and systemic exposure, albeit at low systemic concentrations. Taken together, these recent research advances indicate that although UGT determines the rate and extent of glucuronide generation, the efflux and uptake transporters determine the distribution of these glucuronides into blood and then to various organs for elimination. Recycling schemes impact the apparent plasma half-life of parent compounds and their glucuronides that reach intestinal lumen, in addition to prolonging their gut and colon exposure.

Entities:  

Keywords:  Glucuronidation; UGT; disposition; efflux transporters; glucuronides; interplay; recycling; uptake transporters

Mesh:

Substances:

Year:  2017        PMID: 28266877     DOI: 10.1080/03602532.2017.1293682

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  12 in total

1.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

2.  Pharmacokinetic and Metabolic Profiling of Key Active Components of Dietary Supplement Magnolia officinalis Extract for Prevention against Oral Carcinoma.

Authors:  Dinh Bui; Li Li; Taijun Yin; Xinli Wang; Song Gao; Ming You; Rashim Singh; Ming Hu
Journal:  J Agric Food Chem       Date:  2020-06-04       Impact factor: 5.279

3.  Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.

Authors:  Adebanjo Adegbola; Rana Abutaima; Adeniyi Olagunju; Omotade Ijarotimi; Marco Siccardi; Andrew Owen; Julius Soyinka; Oluseye Bolaji
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 4.  Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms.

Authors:  Song Gao; Nyma Siddiqui; Imoh Etim; Ting Du; Yun Zhang; Dong Liang
Journal:  Biomed Pharmacother       Date:  2021-08-24       Impact factor: 6.529

5.  In silico deconjugation of glucuronide conjugates enhances tandem mass spectra library annotation of human samples.

Authors:  Carolin Huber; Martin Krauss; Vera Reinstadler; Sara Denicolò; Gert Mayer; Tobias Schulze; Werner Brack; Herbert Oberacher
Journal:  Anal Bioanal Chem       Date:  2022-01-26       Impact factor: 4.142

6.  Metabolism of Long-Acting Rilpivirine After Intramuscular Injection: HIV Prevention Trials Network Study 076 (HPTN 076).

Authors:  Herana Kamal Seneviratne; Joseph Tillotson; Julie M Lade; Linda-Gail Bekker; Sue Li; Subash Pathak; Jessica Justman; Nyaradzo Mgodi; Shobha Swaminathan; Nirupama Sista; Jennifer Farrior; Paul Richardson; Craig W Hendrix; Namandje N Bumpus
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-13       Impact factor: 2.205

Review 7.  Targeting the HIF2-VEGF axis in renal cell carcinoma.

Authors:  Toni K Choueiri; William G Kaelin
Journal:  Nat Med       Date:  2020-10-05       Impact factor: 53.440

8.  Oleacein Intestinal Permeation and Metabolism in Rats Using an In Situ Perfusion Technique.

Authors:  Anallely López-Yerena; Maria Pérez; Anna Vallverdú-Queralt; Eleftherios Miliarakis; Rosa M Lamuela-Raventós; Elvira Escribano-Ferrer
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

Review 9.  Harnessing the Power of Microbiome Assessment Tools as Part of Neuroprotective Nutrition and Lifestyle Medicine Interventions.

Authors:  Miguel Toribio-Mateas
Journal:  Microorganisms       Date:  2018-04-25

10.  Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.

Authors:  Herana Kamal Seneviratne; Allyson N Hamlin; Sue Li; Beatriz Grinsztejn; Halima Dawood; Albert Y Liu; Irene Kuo; Mina C Hosseinipour; Ravindre Panchia; Leslie Cottle; Gordon Chau; Adeola Adeyeye; Alex R Rinehart; Marybeth McCauley; Joseph S Eron; Myron S Cohen; Raphael J Landovitz; Craig W Hendrix; Namandjé N Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.